Premium
Genetics and variability in opioid response
Author(s) -
Stamer Ulrike M.,
Bayerer Bettina,
Stüber Frank
Publication year - 2005
Publication title -
european journal of pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.305
H-Index - 109
eISSN - 1532-2149
pISSN - 1090-3801
DOI - 10.1016/j.ejpain.2004.05.008
Subject(s) - pharmacotherapy , pharmacogenetics , opioid , cyp2d6 , adverse effect , medicine , bioinformatics , pharmacogenomics , chronic pain , drug , genetic variation , pharmacology , gene , biology , genetics , psychiatry , genotype , receptor
The human genome project has revealed data on genomic variation which may influence the pharmacological responses. In pain therapy, the genetic background influencing the efficacy of opioid therapy is of special interest. Screening for variations in expression of drug metabolizing enzymes has been suggested as a potential tool for improving patient therapy. CYP2D6 genetic variability is supposed to be a major factor of adverse drug reaction, possibly influencing hospital stay and total costs. Further candidate genes involved in pain perception, pain processing and pain management like opioid receptors, transporters and other targets of pharmacotherapy are under investigation. Aspects of genetic differences influencing efficacy, side effects and adverse outcome of pharmacotherapy will be of importance for future pain management.